|Traded as||NASDAQ: AGIO|
|Headquarters||Cambridge, Massachusetts, United States|
|David Schenkein (CEO)|
|Footnotes / references
Agios Pharmaceuticals is a public American pharmaceutical company focused on developing small-molecule anti-cancer therapeutics targeting cancer cell metabolism via the growth factor pathway. Among the proteins under investigation by the company are IDH1 and IDH2. The company was founded in 2008 (or 2007) by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.:Table 1
In 2012, Agios was named among the defendants in a lawsuit against one of its founders, Craig Thompson, alleging that Thompson used research illegally taken from the Abramson Family Cancer Research Institute in research at Agios.
In April 2017, the company raised $250 million in a new stock offering in anticipation of FDA approval for its first cancer drug.
- Pfeffer, Cary G. (2012). "The biotechnology sector". In Burns, Lawton R. The Business of Healthcare Innovation (Google eBook). Cambridge, United Kingdom: Cambridge University Press. pp. 224, 228. ISBN 9781107024977.
- Anton, Ted (2013). "Chapter 13". The Longevity Seekers (Google eBook). University of Chicago Press. p. 163. ISBN 9780226020938.
- Pollack, Andrew (February 5, 2012). "Sloan-Kettering Chief Is Accused of Taking Research". The New York Times.
- "AGIOS PHARMACEUTICALS, INC.". EDGAR. Form 10-K. U.S. Securities and Exchange Commission. March 18, 2014. Commission File Number:001-36014.
- Huggett, Brady (December 2013). "Burning Bright". Nat. Biotechnol. 31 (12). pp. 1068–71.
- "Celgene, Agios, Launch $1B+ Metabolic Immuno-oncology Alliance - GEN News Highlights - GEN". GEN.
- "Agios bags $250M in offering as cancer drug speeds toward approval". Boston Business Journal. April 19, 2017.
|This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.|